New Mexico Cancer Care Alliance

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2002-01-01

Employees: 11

Market Cap: -

Website: https://nmcca.org

Clinical Trials

Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas

Phase 1

Terminated

Conditions: Sarcoma

First Posted Date: 2009-10-16

Last Posted Date: 2015-09-01

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 17

Registration Number: NCT00996346

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2009-10-16

Last Posted Date: 2016-01-18

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 29

Registration Number: NCT00996060

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Advanced Solid Tumors
Lymphomas

Interventions: Drug: Camptothecin-20-O-Propionate Hydrate (CZ48)

First Posted Date: 2009-07-28

Last Posted Date: 2015-06-18

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 43

Registration Number: NCT00947739

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
University of Texas Health Sciences Center, San Antonio, Texas, United States

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Doxil
Drug: Avastin

First Posted Date: 2009-07-23

Last Posted Date: 2015-07-31

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 46

Registration Number: NCT00945139

Locations: 🇺🇸
New York University Cancer Institute, New York City, New York, United States
🇺🇸
New Mexico Cancer Care Associates, Santa Fe, New Mexico, United States
🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States

Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Irinotecan, oxaliplatin, and cetuximab

First Posted Date: 2009-03-30

Last Posted Date: 2016-06-14

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 61

Registration Number: NCT00871169

Locations: 🇺🇸
University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico, United States
🇺🇸
Hematology Oncology Associates, Albuquerque, New Mexico, United States
🇺🇸
Cancer Center at Presbyterian Hospital, Albuquerque, New Mexico, United States

and more 2 locations

Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers

Not Applicable

Terminated

Conditions: Cancer

Interventions: Drug: Mifepristone

First Posted Date: 2009-01-30

Last Posted Date: 2018-06-29

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 4

Registration Number: NCT00832871

Locations: 🇺🇸
Universtiy of New Mexico - Cancer Center, Albuquerque, New Mexico, United States

The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure

Completed

Conditions: Melanoma

First Posted Date: 2009-01-30

Last Posted Date: 2015-09-28

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 9

Registration Number: NCT00832533

Locations: 🇺🇸
Universtiy of New Mexico - Cancer Center, Albuquerque, New Mexico, United States

Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers

Phase 2

Terminated

Conditions: Extrahepatic Bile Duct Cancer
Hepatocellular Carcinoma
Periampullary Adenocarcinoma
Gallbladder Cancer
Cholangiocellular Carcinoma
Cholangiocarcinoma of the Extrahepatic Bile Duct
Bile Duct Cancer

Interventions: Drug: Cisplatin
Drug: Erlotinib
Drug: Gemcitabine

First Posted Date: 2009-01-30

Last Posted Date: 2018-06-29

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 33

Registration Number: NCT00832637

Locations: 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight

Phase 2

Terminated

Conditions: Advanced Cancer

Interventions: Drug: Remeron (mirtazapine)

First Posted Date: 2009-01-30

Last Posted Date: 2018-04-10

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 13

Registration Number: NCT00832520

Locations: 🇺🇸
University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico, United States
🇺🇸
Universtiy of New Mexico - Cancer Center, Albuquerque, New Mexico, United States

Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung

Not Applicable

Completed

Conditions: Solid Tumors
Lung Cancer
Non Small Cell Lung Cancer

Interventions: Radiation: Stereotactic Body Radiation

First Posted Date: 2009-01-30

Last Posted Date: 2021-05-21

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 44

Registration Number: NCT00832780

Locations: 🇺🇸
Universtiy of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy